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Abstract
Transplantation of unfractionated bone marrow mononuclear cells (BMCs) repairs and/or regenerates the damaged
myocardium allegedly due to secretion from surviving BMCs (paracrine effect). However, donor cell survival after
transplantation is known to be markedly poor. This discrepancy led us to hypothesize that dead donor BMCs might also
contribute to the therapeutic benefits from BMC transplantation. High mobility group box 1 (HMGB1) is a nuclear protein
that stabilizes nucleosomes, and also acts as a multi-functional cytokine when released from damaged cells. We thus studied
the role of extracellular HMGB1 in the effect of BMC transplantation for heart failure. Four weeks after coronary artery
ligation in female rats, syngeneic male BMCs (or PBS only as control) were intramyocardially injected with/without anti-
HMGB1 antibody or control IgG. One hour after injection, ELISA showed that circulating extracellular HMGB1 levels were
elevated after BMC transplantation compared to the PBS injection. Quantitative donor cell survival assessed by PCR for
male-specific sry gene at days 3 and 28 was similarly poor. Echocardiography and catheterization showed enhanced cardiac
function after BMC transplantation compared to PBS injection at day 28, while this effect was abolished by antibody-
neutralization of HMGB1. BMC transplantation reduced post-infarction fibrosis, improved neovascularization, and increased
proliferation, while all these effects in repairing the failing myocardium were eliminated by HMGB1-inhibition. Furthermore,
BMC transplantation drove the macrophage polarization towards alternatively-activated, anti-inflammatory M2
macrophages in the heart at day 3, while this was abolished by HMGB1-inhibition. Quantitative RT-PCR showed that
BMC transplantation upregulated expression of an anti-inflammatory cytokine IL-10 in the heart at day 3 compared to PBS
injection. In contrast, neutralizing HMGB1 by antibody-treatment suppressed this anti-inflammatory expression. These data
suggest that extracellular HMGB1 contributes to the effect of BMC transplantation to recover the damaged myocardium by
favorably modulating innate immunity in heart failure.
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Introduction
Transplantation of stem or progenitor cells is an emerging
approach to repair and/or regenerate damaged myocardium
undergoing adverse ventricular remodeling. Unfractionated bone
marrow mononuclear cells (BMCs) contain several kinds of stem/
progenitor cells and are the most frequently used donor cell type in
clinical cell therapy to the heart [1]. The therapeutic effect of
BMC transplantation in not only acute myocardial infarction (MI)
but also post-MI chronic heart failure (ischemic cardiomyopathy)
has been confirmed in animal and human studies [1–3]. Because
injected BMCs do not vigorously differentiate to functioning
cardiomyocytes or vascular cells in vivo, the major mechanism of
the therapeutic effects is proposed to be their secretion of
cytokines, chemokines and growth factors that help repair of the
damaged myocardium suffering post-MI adverse remodeling [1–
3]. However, the precise mechanism of this ‘‘paracrine effect’’
remains uncertain.
Interestingly, cardiac function recovery by BMC transplantation
occurs despite of markedly poor donor cell survival [1,3,4]. It has
also been shown that active secretion from BMCs is less extensive
compared to other donor cell types [5,6]. It was also reported that
injection of extract of dead BMCs by freeze-thaw cycles induces
the similar therapeutic effect to injection of living BMCs [7].
These findings led us to hypothesize that dead donor BMCs might
be a supplementary or alternative source of the paracrine
mediators, which could contribute to the repair of the failing
myocardium.
High-mobility group box 1 (HMGB1) was initially identified as
a nuclear protein that regulates transcriptional factors to stabilize
the nucleosome [8]. This molecule is also known to be actively
secreted from activated inflammatory cells and also passively
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released from dead cells [9–11]. Extracellular HMGB1 induces
and intensifies inflammation in most cases, while it can also
operate to attenuate inflammation and enhance the healing of
damaged tissues, according to the form/amount of HMGB1 and
nature of the tissues [9–12]. In the heart, there is increasing
evidence that extracellular HMGB1 attenuates myocardial dam-
age and induces recovery/regeneration [13–18], though there are
contradicting reports [19,20]. We have demonstrated that
HMGB1 administration achieved the similar benefits to the
BMC-mediated paracrine effects, including decreased fibrosis,
increased vascular formation, attenuated cardiomyocyte hypertro-
phy, and attenuated inflammation in a rat ischemic cardiomyop-
athy model [17]. It has also been reported that extracellular
HMGB1 augments tissue regeneration through activating endog-
enous progenitor cells [15,21].
Collectively, these data formed a hypothesis that extracellular
HMGB1 released from dead donor cells contributes to the
paracrine effect of BMC transplantation to repair the post-MI
failing myocardium and to improve cardiac performance.
Materials and Methods
Ethics Statement
All studies were performed with the approval of the UK Home
Office (Project Licence Number: 70/7254). The investigation
conforms to the Principles of Laboratory Animal Care formulated
by the National Society for Medical Research and the Guide for
the Care and Use of Laboratory Animals (US NIH Publication,
1996). All animal surgery was performed under inhalation
anesthesia of isoflurane and administration of buprenorphine
hydrochloride was made just after surgery to reduce postoperative
pain, and all efforts were made to minimize suffering. Surgical
procedures, cardiac function measurement, and sample analyses
were performed in a blinded manner.
BMC Collection
Bone marrow was isolated from both femurs and tibias of male
Lewis rats (150–200 g; Charles River, UK), from which BMCs
(mononuclear cells) were purified by Ficoll-Paque gradient
centrifugation (GE Healthcare) as previously described [3]. Flow
cytometry analysis (FACSAria, BD Biosciences) using monoclonal
anti-rat CD34 (Santa-Cruz) and anti-rat CD45 (BD Pharmingen)
antibodies showed that 4.661.7% of the BMCs were positive for
CD34 and 75.564.3% were positive for CD45 (Figure S1). To
trace the injected cells, BMCs were labeled with CM-DiI
(Molecular Probes) before transplantation according to the
company’s protocol. The viability of donor BMCs just before
injection measured by trypan blue staining was 97.160.6% (n = 11
animals).
Assessment of Cardiac Function
Cardiac function and dimensions pre and post treatment were
measured by using echocardiography (Vevo2770, VisualSonics)
as previously described [3,17]. Diastolic and systolic LV endocar-
dial areas at the papillary muscle level were measured from
parasternal short-axis views, from which LV fractional area
change (LVFAC) was calculated. Post treatment hemodynamics
parameters were measured by catheterization (SRP2320/
PVAN3.2, Millar Instruments and Chart 5 software, ADInstru-
ments) as described previously [22].
Generation of Ischemic Cardiomyopathy and Cell
Transplantation in Rat
Female Lewis rats (150–200 g, Charles River) underwent left
coronary artery ligation as described previously [3,17,23,24]. Four
weeks later, the animals that showed appropriate cardiac
dysfunction (LVFAC 22–32%; base line in intact
rats = 61.661.7% [n = 5]) by echocardiography were chosen and
randomly assigned to 4 treatment groups; intramyocardial
injection of 16107 syngeneic male BMCs (BMC group), injection
of BMCs with 50 mg anti-HMGB1 neutralizing antibody (Medical
& Biological Laboratories; AB group), injection of BMCs with
50 mg control IgG (Sigma-Aldrich; IgG group), and injection of
PBS only (CON group). BMCs were suspended in 200 ml of PBS
and intramyocardial injection was performed into 2 sites (100 ml
each) of the LV free wall, targeting the border areas [3].
To optimize the antibody dose, 16107 BMCs were injected with
0, 10, 50, or 100 mg of anti-HMGB1 antibody in the same model
(n$3). At day 28, LVFAC was 31.561.2, 30.361.5, 26.661.3,
and 26.461.8%, respectively. Then, 50 mg antibody was used in
the main study.
Detection of Released HMGB1
Peripheral blood was collected, from which serum was obtained
by centrifugation. HMGB1 levels in the serum were determined in
duplicate using a commercial ELISA kit (IBL international
GMBH) according to the manufacture’s instruction.
Histological Analysis
The hearts were excised, fixed with 4% paraformaldehyde,
embedded in OCT compound, and quickly frozen in liquid
nitrogen. Cryosections were cut and incubated with biotin
conjugated Griffonia simplicifolia lectin I-isolectin B4 (1:100,
Vector), monoclonal anti-rat CD68 antibody (1:100, AbD
Serotec), monoclonal anti-rat CD86 antibody (1:50, BD), mono-
clonal anti-rat CD163 antibody (1:100, AbD Serotec), monoclonal
anti-rat Ki-67 antibody (1:50, DakoCytomation), and/or poly-
clonal anti-rat cardiac troponin-T (cTnT) antibody (1:200,
HyTest) followed by visualization using appropriate fluorophore-
conjugated secondary antibodies (Molecular Probes). Samples
were observed by a fluorescence microscopy (BZ8000, Keyence)
with or without nuclear counter-staining using 49, 6-diamidino-2-
phenylindole (DAPI). Ten different fields were randomly selected
in each border area of the samples and assessed. Another set of
sections were stained with 0.1% picrosirius red, which enabled
calculation of extracellular collagen volume fraction in border area
by using NIH image-analysis software [3,17,22].
Quantitative Analysis of Donor Cell Survival
Genomic DNA was extracted from the whole LV samples of
female rats. To detect donor cell (male) survival, expression of the
Y chromosome-specific sry gene in these samples was assessed by
real-time polymerase chain reaction (PCR; Prism 7900HT,
Applied Biosystems). The sry levels were normalized to the DNA
amount using the autosomal single copy gene, oesteopontin. The
number of surviving donor cells was estimated by correcting the
relative sry expression using a standard curve as previously
described [3,17,22].
Measurements of Myocardial Gene Expression
Total RNA was extracted from the whole LV samples and
assessed for myocardial expression of IL-1b, TNF-a, and IL-10 by
quantitative RT-PCR (Prism 7900HT, Applied Biosystems) as
previously described [22]. TaqMan primers and probes were
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purchased from Applied Biosystems. Expression was normalized
using Ubiquitin C.
Statistical Analysis
All values are expressed as mean6SEM. Statistical comparison
of the data was performed using the student’s unpaired t-test for
the analysis of circulating HMGB1 levels. All other data were
analyzed with one-way ANOVA followed by Fisher’s post-hoc
analysis to compare groups. A value of p,0.05 was considered
statistically significant.
Results
Poor Donor Cell Survival and Increased Extracellular
HMGB1 After BMC Transplantation
Female rats suffering ischemic cardiomyopathy were randomly
assigned to 4 groups; intramyocardial injection of syngeneic male
BMCs (BMC group), intramyocardial injection of male BMCs
with anti-HMGB1 neutralizing antibody (AB group), intramyo-
cardial injection of male BMCs with control IgG (IgG group), and
intramyocardial injection of PBS only (CON group). After each
treatment, quantitative PCR for the male-specific sry gene
demonstrated that donor cell survival after BMC transplantation
was poor similarly in the BMC, AB, and IgG groups; below 10%
at day 3, further decreasing to below 1% by day 28 (Figure 1A).
Histological analysis detected islet-like clusters of donor cells at day
3 after BMC transplantation (Figure 1B). ELISA showed that the
circulating extracellular HMGB1 level was 2.5-fold elevated one
hour after BMC transplantation, compared to the PBS injection
control (Figure 1C).
Abolished BMC Transplantation-induced Cardiac
Function Recovery by HMGB1-inhibition
Four weeks after BMC transplantation (BMC group), echocar-
diography and cardiac catheterization consistently demonstrated
that both systolic and diastolic LV function, in terms of LV
fractional area change, max and min dP/dt, and systolic pressure,
was improved compared to the control (CON group; Figure 2).
Enlargement of LV systolic endocardial area in the control group
was attenuated by BMC transplantation. Of note, these effects
were largely abolished by HMGB1-inhibition (AB group), but not
by control IgG administration (IgG group), indicating an
important role of extracellular HMGB1 in the therapeutic benefits
of BMC transplantation.
Elimination of BMC Transplantation-induced Tissue
Recovery by HMGB1-inhibition
To investigate the mechanism by which extracellular HMGB1
released in BMC transplantation improved post-MI cardiac
function, we performed a set of histological studies with a focus
on the paracrine effect. Consistent to previous reports [3], BMC
transplantation (BMC group) attenuated post-MI pathological
fibrosis, improved neovascular formation, and increased prolifer-
ation activity in the border areas at day 28, compared to the
control (CON group; Figure 3 and Figure S2). All these
paracrine effects were, however, eliminated by HMGB1-inhibition
(AB group), but not by IgG administration (IgG group),
corresponding to the cardiac function change as shown in Figure 2.
Modulation of M2/M1 Macrophage Polarization by BMC
Transplantation through HMGB1
Additional immunolabeling showed that BMC transplantation
increased myocardial accumulation of CD68+ pan-macrophages
compared to the control (Figure 4A and Figure S3A, B). Here,
the increase in CD86+ classically-activated pro-inflammatory (M1)
macrophages was trivial (Figure 4B and Figure S3D, E), while
the enhancement of CD163+ alternatively-activated (M2) macro-
phages was more obvious (Figure 4C and Figure S3G, H). As a
result, the ratio of M2/M1 macrophage in the BMC group (92.9/
36.9 = 2.52) was increased from 56.3/28.4 = 1.98 in the CON
group. Of note, HMGB1-inhibition abolished the enhancement of
CD163+ M2 macrophages (Figure 4C and Figure S3I) and
exacerbated the increase in CD86+ M1 macrophages (Figure 4B
and Figure S3F), thus largely reducing the M2/M1 ratio to
67.6/62.9 = 1.07. These results suggest that the HMGB1-mediat-
ed shift of macrophage polarization towards anti-inflammatory
M2 macrophages might play a role in the BMC transplantation-
induced myocardial recovery.
Quantitative RT-PCR showed that myocardial expression of
the anti-inflammatory cytokine, IL-10, tended to be elevated by
BMC transplantation compared to the control, while this was
totally eliminated by inhibiting HMGB1 (Figure 4D). IL-10 is
known to be secreted by alternatively activated M2 macrophages
and also by Th2 cells that induce M2 macrophage differentiation
[9,25,26]. The expression of IL-1b or TNF-a was not affected by
either BMC transplantation or HMGB1-inhibition (Figure 4E,
F).
Figure 1. Poor donor cell survival and HMGB1 leakage after
BMC transplantation. (A) Quantitative PCR for the male specific sry
gene showed that the survival of male donor cells in female hearts was
poor similarly in the BMC (BMC injection), IgG (BMC+control IgG
injection), and AB (BMC+anti-HMGB1 antibody injection) groups at both
days 3 and 28; n = 5,7 in each point. (B) Clusters of DiI-labeled (red)
donor BMCs were detected in the heart at day 3 after BMC
transplantation. A higher magnification image of the yellow frame is
shown. Green = cardiomyocytes (cTnT); blue = nuclei (DAPI). Scale
bar = 300 mm. (C) ELISA showed that the circulating HMGB1 level was
increased at 1 hour in the BMC group compared to the PBS injection
control (CON group). *:p,0.05 versus the CON group, mean6SEM for
n = 5 each.
doi:10.1371/journal.pone.0076908.g001
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Discussion
Using a post-MI ischemic cardiomyopathy model in rat, we
demonstrated that the BMC transplantation-mediated benefits,
including increased neovascular formation, reduced collagen
deposition, increased proliferation activity, favorable modulation
of macrophage polarization, and resultant improvement of cardiac
function, were all eliminated by antibody-neutralization of
HMGB1. These data suggest that extracellular HMGB1 plays a
role in the effects of BMC transplantation to recover the failing
myocardium undergoing post-MI adverse remodeling and to
improve global cardiac function. This finding is validated by the
consistency with the previous report demonstrating that admin-
istration of recombinant HMGB1 protein achieved the same
benefits as the BMC transplantation-mediated effects using the
similar ischemic heart failure model in rats [17].
In view of the origin of extracellular HMGB1 occurring after
BMC transplantation into post MI chronic heart failure, there are
4 theoretically possible sources: (i) passive release from dead donor
BMCs, (ii) passive release from dead host (endogenous) cells, (iii)
active secretion from surviving donor BMCs, and (iv) active
secretion from host (endogenous) cells. It is likely that the major
origin may be (i) passive release from dead donor BMCs, given the
following information. [I] Survival of donor BMCs was largely
limited, indicating that there was a considerable amount of donor
cell death; [II] In this model of ischemic cardiomyopathy, death/
damage of host cells in the heart and other organs by BMC
injection is unlikely to be substantial; [III] There was an increased
level of circulating HMGB1 as early as 1 hour after BMC
injection. This time course is too rapid for inflammatory cells to
actively secrete HMGB1 via transcription after stimulation [9,27].
Having said these, we could not eliminate the possibility that
extracellular HMGB1 from other sources, particularly from
endogenous sources (host cells), might contribute to the paracrine
effect of BMC transplantation. Experiments using HMGB1-
deficient BMCs, either by knockout or knockdown, as donor
would provide useful information to this point. However, HMGB1
knockout mice die immediately after birth [28], while on the other
hand reproducible and satisfactory knockdown in primary rat
unfractionated BMCs has not been established.
The role of extracellular HMGB1 to attenuate myocardial
damage and to induce recovery and/or regeneration remains
controversial [13–20]. This discrepancy may be relevant to
different types of HMGB1 and different conditions of the host
myocardium. In the settings of acute MI (without cell transplan-
tation), a large amount of HMGB1 is actively secreted from
accumulated inflammatory cells in addition to HMGB1 passively
released from a large number of dead host cardiac cells. The
dynamics and functions of these different types of HMGB1 are
likely to be distinct, due to different phosphorylation, acetylation,
and formation of complexes by binding other pathogenic
molecules [9,11]. Delicate balance between these types of
extracellular HMGB1 may affect the overall effect, whether
beneficial or harmful, of HMGB1. Our study therefore used a
post-MI ischemic cardiomyopathy model to exclude these
contaminating factors. The degree of HMGB1 both from
inflammatory cells and dead host cardiac cells in this model is
presumed to be much less than that in acute MI settings, and the
frequency of host cardiac cell death by BMC injection is also
negligible, compared to donor cell death.
Figure 2. Abolished BMC transplantation-induced cardiac function recovery by HMGB1-inhibition. Cardiac parameters were measured
by echocardiography (A–D) and catheterization (E–H) on day 28 after each treatment. Cardiac function was improved by BMC transplantation (BMC
group) compared to the PBS injection control (CON group), while this effect was eliminated by antibody neutralization of HMGB1 (AB group), but not
by control IgG administration (IgG group). LVFAC, left ventricular fractional area change; ECA, endocardial area. *:p,0.05 versus the CON group,
{:p,0.05 versus the BMC group. `:p,0.05 versus the IgG group, mean6SEM for n = 8,10 in each group.
doi:10.1371/journal.pone.0076908.g002
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It will be interesting to investigate whether the present results in
unfractionated BMCs are applicable to other types of donor cells.
There are published data in other cell types that appear to be
contradicting to our findings in BMCs at a glance. Ziebart et al.
have reported that the persistence of donor cells contributes to the
therapeutic effect of transplantation of endothelial progenitor cells
Figure 3. Eliminated BMC transplantation-induced tissue recovery by HMGB1-inhibition. Reduced extracellular collagen deposition (A–
C; picrosirius red = red), increased capillary density (D–F; Isolectin B4 = red), and increased proliferation (G–I; Ki67 = red; nuclei = blue; cTnT = green)
were observed in the border areas at day 28 after BMC transplantation (BMC group), compared to the PBS control (CON group). These effects were all
abolished by anti-HMGB1 antibody neutralization (AB group), but not by control IgG administration (IgG group). Representative images of only BMC
and AB groups are present (see Figure S2 for additional images). Scale bars = 50 mm in A, B, G, H and 30 mm in D, E. *:p,0.05 versus the CON
group, {:p,0.05 versus the BMC group, `:p,0.05 versus the IgG group, mean6SEM for n = 5,7 in each group.
doi:10.1371/journal.pone.0076908.g003
Figure 4. Modulation of innate immunity by BMC transplantation via released HMGB1. Accumulation of CD68+ pan-macrophages (A),
CD86+ classically-activated pro-inflammatory M1 macrophages (B), and CD163+ alternatively-activated anti-inflammatory M2 macrophages (C) in the
border areas at day 3 after each treatment was assessed by immunolabeling. See Figure S3 for representative images. Myocardial expression of IL-10
(D), IL-1b (E)), and TNF-a (F) at day 3 after each treatment was measured by quantitative RT-PCR. *:p,0.05 versus the CON group, {:p,0.05 versus the
BMC group, mean6SEM for n = 5,7 in each group.
doi:10.1371/journal.pone.0076908.g004
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by using the inducible suicide gene [29]. Laflamme et al. have
demonstrated that increase of donor cell presence (thus reducing
donor cell death) by the treatment with pro-survival factors
enhances therapeutic effects of transplantation of embryonic stem
cell-derived cardiomyocytes [30]. However, in contrast, in the case
of unfractionated BMCs, Yeghiazarians et al. reported that
ultrasound-guided injection of extract of dead BMCs by freeze-
thaw cycles achieves the similar therapeutic effect to injection of
living BMCs [7], supporting our findings. This cell type-dependent
controversy may suggest that the impact of HMGB1 released from
dead donor cells to recover the damaged myocardium could be
diluted/hidden in the case of transplantation of ‘‘more proficient’’
cells such as endothelial progenitor cells and embryonic stem cell-
derived cardiomyocytes that have more substantial abilities of
beneficial differentiation, secretion, and/or contraction. In addi-
tion, the extent and/or types of donor cell death after transplan-
tation may vary according to donor cell types, affecting the release
of HMGB1. Differences in the condition of the host heart, i.e.
acute MI versus post-MI ischemic cardiomyopathy, may also
influence the impact of extracellular HMGB1 from donor cells.
Further studies to elucidate the role of extracellular HMGB1 in
different donor cell types in the same experimental setting are
warranted.
Macrophages are an important player in the progress and
recovery of post-MI adverse ventricular remodeling [31,32]. It has
also been shown that HMGB1 and receptor for advanced
glycation endproducts signaling play a role in the macrophage-
involved tissue repair mechanism in the peripheral nerve [33].
Recent research has shown that macrophages can be functionally
polarized into classically-activated M1 (pro-inflammatory) or
alternatively-activated M2 (anti-inflammation and tissue healing)
phenotypes according to the environmental condition [9,26].
Stimulation with IFN-c or TNF-a drives the macrophages into the
M1 phenotype, which is characterized by a strong pro-inflamma-
tory ability. In contrast, exposure to IL-4 or IL-13 generates M2
macrophages, which attenuate inflammation and enhance tissue
recovery and healing. Importance of this polarization balance in
the repair of damaged organs, including the heart, has been
reported [9,26]. Our results here uncovered that BMC transplan-
tation enhanced ‘‘beneficial’’ M2 macrophages in the heart, for
which extracellular HMGB1 was responsible. Therefore,
HMGB1-mediated modulation of the macrophage’s polarization
towards the M2 phenotype might be a part of the mechanism by
which BMC transplantation recovers the damaged myocardium
and improves cardiac function. Further study should focus on
elucidation of the molecular mechanism of extracellular HMGB1
to modulate the M1/M2 macrophage polarization, in a simpler
model.
A limitation of this study may be that our conclusion is based on
the antibody neutralization experiments, which might carry a risk
(though unlikely) of unexpected artifacts, such as unpredictable
actions of the immune complexes generated. Investigations using
HMGB1-deficient cells, either by knockout or knockdown, could
add useful validation of our results, but these were not practical
due to technical limitations as discussed above. Nonetheless, the
consistency with the previous evidence that administration of
HMGB1 protein induces the same effects as the BMC transplan-
tation [17] supports our results.
In summary, our results demonstrated that extracellular
HMGB1, which is derived from dead donor cells at least in part,
plays a role of the effect of BMC transplantation to recover the
damaged tissue by favorably modulating innate immunity in heart
failure. This novel proof-of-concept will imply an important clue
to further understand and refine BMC transplantation therapy for
heart failure.
Supporting Information
Figure S1 Characterisation of BMCs by flow cytometry
analysis. Flow cytometry analysis showed that 4.661.7%of
collected rat BMCs were positive for CD34 and 75.564.3% were
positive for CD45. A representative image is presented.
(TIF)
Figure S2 Supplement to Figure 3; HMGB1-inhibition
abolished myocardial recovery by BMC transplantation.
A–D: Representative images of picrosirius red staining. Scale
bar = 50 mm. E–H: Representative images of islectin-B4 staining
(red). Scale bar = 30 mm. I–L: Representative images of immu-
nofluorescent labelling with Ki-67 (red); blue = nuclei (DAPI).
Scale bar = 50 mm.
(TIF)
Figure S3 Supplement to Figure 4; Inflammation was
modulated by BMC transplantation through HMGB1.
Representative images of immunofluorescent labelling with CD68
(A–C), CD86 (D–F), and CD163 (G–I). Green is for each target
molecule; blue for nuclei (DAPI). Scale bars = 50 mm.
(TIF)
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